ROIVANT SCIENCES LTD. Increase (Decrease) in Other Operating Assets and Liabilities, Net
ROIVANT SCIENCES LTD. (ROIV) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of -$5.02 million for the 9-month period ending 2025-12-31, per its 10-Q filed 2026-02-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-02-06
- ROIVANT SCIENCES LTD. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-12-31 was -$8.30M, a 229.77% decline year-over-year.
- ROIVANT SCIENCES LTD. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was $3.21M, a 84.37% decline year-over-year.
- ROIVANT SCIENCES LTD. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-06-30 was $71.00K.
- ROIVANT SCIENCES LTD. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2024-12-31 was $6.39M.
- ROIVANT SCIENCES LTD. increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was -$3.30M.
- ROIVANT SCIENCES LTD. increase (decrease) in other operating assets and liabilities, net for fiscal 2022 was -$34.59M, a 191.40% decline from fiscal 2021.
- ROIVANT SCIENCES LTD. increase (decrease) in other operating assets and liabilities, net for fiscal 2021 was $37.84M.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month as first filed | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month as first filed | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month as first filed | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$8.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | -$5.09M derived: sum of 2 quarters · filed 2026-02-06 | -$5.02M 10-Q · filed 2026-02-06 | |||||
| 2025-09-30 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $3.28M 10-Q · filed 2025-11-10 | ||||||
| 2025-06-30 | $71.00K 10-Q · filed 2025-08-11 | |||||||
| 2024-12-31 | $6.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $26.91M derived: sum of 2 quarters · filed 2026-02-06 | $14.64M 10-Q · filed 2026-02-06 | |||||
| 2024-09-30 | $20.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $8.24M 10-Q · filed 2025-11-10 | ||||||
| 2024-06-30 | -$12.27M 10-Q · filed 2025-08-11 | |||||||
| 2023-12-31 | -$27.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | -$32.56M derived: sum of 2 quarters · filed 2025-02-10 | -$41.99M 10-Q · filed 2025-02-10 | -$41.95M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-09-30 | -$5.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | -$14.57M 10-Q · filed 2024-11-12 | -$14.53M derived: sum of 3 quarters · filed 2024-11-12 | -$8.70M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$9.43M 10-Q · filed 2024-08-09 | -$9.39M derived: sum of 2 quarters · filed 2024-08-09 | -$3.56M derived: sum of 3 quarters · filed 2024-08-09 | -$9.60M derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2023-03-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $5.87M derived: sum of 2 quarters · filed 2024-02-13 | -$172.00K derived: sum of 3 quarters · filed 2024-02-13 | -$3.30M 10-K · filed 2023-06-28 | ||||
| 2022-12-31 | $5.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | -$210.00K derived: sum of 2 quarters · filed 2024-02-13 | -$3.34M 10-Q · filed 2024-02-13 | -$26.81M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-09-30 | -$6.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | -$9.17M 10-Q · filed 2023-11-13 | $17.18M 10-Q · filed 2022-11-14 | -$32.64M derived: sum of 3 quarters · filed 2023-11-13 | -$34.63M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | -$3.13M 10-Q · filed 2023-08-14 | $6.45M 10-Q · filed 2022-08-15 | -$26.60M derived: sum of 2 quarters · filed 2023-08-14 | -$28.59M derived: sum of 3 quarters · filed 2023-08-14 | -$31.87M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$23.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$25.46M derived: sum of 2 quarters · filed 2023-06-28 | -$28.73M derived: sum of 3 quarters · filed 2023-06-28 | -$34.59M 10-K · filed 2023-06-28 | $11.38M 10-K · filed 2022-06-28 | |||
| 2021-12-31 | -$1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | -$5.27M derived: sum of 2 quarters · filed 2023-02-13 | -$11.12M 10-Q · filed 2023-02-13 | $4.95M 10-Q · filed 2022-02-14 | -$607.00K derived: sum of 4 quarters · filed 2023-02-13 | |||
| 2021-09-30 | -$3.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | -$9.13M 10-Q · filed 2022-11-14 | -$7.60M 10-Q · filed 2021-11-15 | $1.38M derived: sum of 3 quarters · filed 2022-11-14 | $30.60M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | -$5.85M 10-Q · filed 2022-08-15 | -$3.71M 10-Q · filed 2021-09-21 | $4.66M derived: sum of 2 quarters · filed 2022-08-15 | $33.88M derived: sum of 3 quarters · filed 2022-08-15 | $28.25M derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | $10.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $39.73M derived: sum of 2 quarters · filed 2022-06-28 | $34.10M derived: sum of 3 quarters · filed 2022-06-28 | $37.84M 10-K · filed 2022-06-28 | ||||
| 2020-12-31 | $29.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-14 | $23.59M derived: sum of 2 quarters · filed 2022-02-14 | $27.33M 10-Q · filed 2022-02-14 | |||||
| 2020-09-30 | -$5.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-15 | -$1.89M 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | $3.74M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |